These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38274528)

  • 1. Corrigendum: High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine.
    Galvez SJ; Altice FL; Meteliuk A; Ivasiy R; Machavariani E; Farnum SO; Fomenko T; Islam Z; Madden LM
    Front Public Health; 2023; 11():1359708. PubMed ID: 38274528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine.
    Galvez SJ; Altice FL; Meteliuk A; Ivasiy R; Machavariani E; Farnum SO; Fomenko T; Islam Z; Madden LM
    Front Public Health; 2023; 11():1231581. PubMed ID: 38098837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine.
    Meteliuk A; Galvez de Leon SJ; Madden LM; Pykalo I; Fomenko T; Filippovych M; Farnum SO; Dvoryak S; Islam ZM; Altice FL
    J Subst Abuse Treat; 2021 Feb; 121():108164. PubMed ID: 33191004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
    Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
    Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 Pandemic.
    Lee K; Zhao Y; Merali T; Fraser C; Kozicky JM; Mormont MC; Conway B
    J Addict Med; 2023 Nov-Dec 01; 17(6):e374-e381. PubMed ID: 37934531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine.
    Schaub M; Chtenguelov V; Subata E; Weiler G; Uchtenhagen A
    Int J Drug Policy; 2010 May; 21(3):229-33. PubMed ID: 19926271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine.
    Madden L; Bojko MJ; Farnum S; Mazhnaya A; Fomenko T; Marcus R; Barry D; Ivanchuk I; Kolomiets V; Filippovych S; Dvoryak S; Altice FL
    Int J Drug Policy; 2017 Nov; 49():48-53. PubMed ID: 28957756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England.
    Aldabergenov D; Reynolds L; Scott J; Kelleher MJ; Strang J; Copeland CS; Kalk NJ
    Int J Drug Policy; 2022 Dec; 110():103877. PubMed ID: 36265326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Marcus R; Pykalo I; Madden L; Filippovich S; Dvoriak S; Altice FL
    J Subst Abuse Treat; 2018 Apr; 87():1-8. PubMed ID: 29471921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences.
    McDonald R; Bech AB; Clausen T
    BMC Health Serv Res; 2023 Sep; 23(1):965. PubMed ID: 37679751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum: Chain mediations of perceived social support and emotional regulation efficacy between role stress and compassion fatigue: insights from the COVID-19 pandemic.
    Zhang Y; He H; Yang C; Wang X; Luo J; Xiao J; Fu B; Chen Y; Ma C
    Front Public Health; 2023; 11():1346956. PubMed ID: 38239789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
    Corace K; Suschinsky K; Wyman J; Leece P; Cragg S; Konefal S; Pana P; Barrass S; Porath A; Hutton B
    Int J Drug Policy; 2022 Apr; 102():103573. PubMed ID: 35123246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
    Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.
    Jordan CJ; Cao J; Newman AH; Xi ZX
    Neuropharmacology; 2019 Nov; 158():107609. PubMed ID: 31009632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Polonsky M; Marcus R; Bojko MJ; Filippovych S; Springer S; Dvoriak S; Altice FL
    Drug Alcohol Depend; 2016 Aug; 165():213-20. PubMed ID: 27370527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine.
    Morozova O; Dvoriak S; Pykalo I; Altice FL
    Drug Alcohol Depend; 2017 Apr; 173():132-138. PubMed ID: 28242537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials.
    Klimas J; Hamilton MA; Gorfinkel L; Adam A; Cullen W; Wood E
    Syst Rev; 2021 Aug; 10(1):216. PubMed ID: 34362464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary on Farnum et al.: Agonist maintenance in Ukraine-ambivalence, success and moving forward.
    Woody GE
    Addiction; 2021 Jan; 116(1):94-95. PubMed ID: 33001461
    [No Abstract]   [Full Text] [Related]  

  • 20. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
    Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
    Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.